Does chemo work for lymphoma

Chemotherapy for lymphoma is a real tool with real limits. The evidence shows it can shrink tumors and extend life, but the numbers vary hugely by lymphoma type, stage, and your age.

The studies here are mostly small, single-arm, or retrospective. None compare chemo to no treatment in a modern randomized trial. The best evidence comes from the NHL-B2 trial, which compared different chemo schedules in elderly patients with aggressive lymphoma. CHOP-14 (given every two weeks) produced a 76% complete remission rate and 53% five-year survival, versus 60% remission and 41% survival for the standard three-week schedule [24]. That is a real difference, but it is still a 47% chance of death within five years.

For peripheral T-cell lymphoma, a rare and aggressive type, the numbers are worse. One study of 156 patients found a five-year survival of only 39% [18]. Another found that anthracycline-based chemo improved median survival to 19 months versus 4.5 months with non-anthracycline regimens [23]. That is a gain, but measured in months, not years.

For older patients, the toxicity is severe. In a study of patients over 80 with diffuse large B-cell lymphoma, full-dose doxorubicin did not improve survival after adjustment, and completing full-dose therapy was rare [35]. In Hodgkin lymphoma patients over 60, treatment-related mortality hit 5% and only 59% of the planned dose was delivered [37].

The mechanism matters here. Chemotherapy kills rapidly dividing cells, which includes lymphoma cells but also your bone marrow, gut lining, and hair follicles. The collateral damage is not a side effect, it is the mechanism. The colloidal frame I work from would ask what this does to blood viscosity and zeta potential. Chemo drugs like doxorubicin are known to cause oxidative damage to the glycocalyx and red cell membranes, which can worsen blood sludging. The evidence here does not study that, but it is a plausible contributor to the fatigue, cognitive issues, and cardiovascular damage that patients report.

My call: chemotherapy can shrink lymphoma and extend life, especially for aggressive B-cell types, but the benefit is partial and comes with substantial toxicity. For indolent lymphomas like MALT, the evidence shows no survival difference between chemo, surgery, or observation after antibiotics fail [25]. For aggressive lymphomas, the gain is real but modest. Confidence: moderate. The evidence is thin on long-term quality of life and on how chemo affects the colloidal stability of blood.